[Mitomycin C in refractive corneal surface surgery with the excimer laser: first experience and review of the literature].
Haze formation with loss of corneal transparency and surface irregularities and myopic regression are the major complications after corneal refractive surface surgery. The use of mitomycin C (MMC) with its antibiotic and antineoplastic properties is intended to inhibit wound healing mechanisms leading to subepithelial fibrosis. We report the use of MMC to achieve visual rehabilitation in the re-treatment of 3 eyes of 2 patients following refractive corneal surgery. According to the literature, the local use of MMC 0.02 % for 2 minutes is safe and enables one to treat and prevent stromal haze and myopic regression and allows a reduction of the postoperative topical pharmacotherapy. Results are still limited due to small case numbers and short follow-up periods.
Kottler
U B
UB
Augenklinik mit Poliklinik der Johannes Gutenberg-Universität Mainz.
Dick
H B
HB
D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant / Q000379:methods; D003318:Corneal Opacity / Q000209:etiology* / Q000517:prevention & control*; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins; D049008:Keratectomy, Subepithelial, Laser-Assisted / Q000009:adverse effects* / Q000379:methods; D008297:Male; D016685:Mitomycin / Q000008:administration & dosage*; D009216:Myopia / Q000209:etiology* / Q000517:prevention & control*; D009687:Nuclear Proteins; D010750:Phosphoproteins; D012030:Refractive Errors / Q000150:complications / Q000188:drug therapy*; D054140:Refractive Surgical Procedures; D014945:Wound Healing / Q000187:drug effects
D000903:Antibiotics, Antineoplastic; D047908:Intracellular Signaling Peptides and Proteins; D009687:Nuclear Proteins; D010750:Phosphoproteins; C491352:Tcof1 protein, mouse; D016685:Mitomycin